InSitu Biologics intends to pursue a strategic licensing transaction with a worldwide Animal Care Company that it believes could be of significant financial benefit to the Company.
The global pet care market is expected to reach USD 202.6 billion by 2025, according to a new report by Grand View Research, Inc. Rise in the adoption of pets and growing demand for premium care products, and veterinarian care are a few factors expected to drive market growth.
According to Wakefield Research, 69% of millennials are likely to use technology to keep track of their pets. InSitu believes that the use of technology for animal healthcare, combined with the early inroads made by Aratana Therapeutics with their sustained release drug, Nocita™, could greatly enhance the value of InSitu’s AniGel BioHydrogel Analgesic Product.
AniGel has repeatedly been proven superior to the Nocita product in 8 different studies, and in three different species.
Find our study at the Journal of Pain Research titled:
“An evaluation of the analgesic effect of AnestaGel™ on mechanical allodynia in a rat model of postoperative incisional pain”